Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

Contact Us

Search

NSCLC

Onco_background

Oncology Weekly News - July 7th 2025

🔬🧬 Oncology Updates: Glioma Drug Win, HER2+ Cancer Trials, First-in-Class ADC…

Onco_background

Oncology Weekly News - May 26th 2025

🧬🚀Oncology Update: Breakthrough Trials, Drug Approvals & New Therapies.…

Onco_background

Oncology Weekly News - May 19th 2025

Latest breakthroughs in oncology research: FDA and EU Approvals, Key Trial Wins…

Onco_background

Oncology Weekly News - May 5th 2025

🧬🚀 Latest breakthroughs in oncology research! 🏥✨ From innovative trial results…

ELCC 2025_Preview_by_LucidQuest

ELCC 2025 Preview: Key Lung Cancer Highlights to Watch

ELCC 2025 at a glance Looking toward ELCC 2025, LucidQuest highlights…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B

Tags

ADC therapy Allurion Angelman Syndrome antimicrobiotics pipeline ASGCT 2025 asthma treatment CAR T Therapy CBD research CGM Chemical Pollution co-pilot Colorectal Cancer Columvi contraceptives DASH Diet Digital Inhaler dostarlimab exoskeleton Galderma GeoVax Glymphatic System HCPs HIV Research immunooncology India Pharma insulin access ISC 2025 Longevity industry mCRC Medical Breakthroughs microbiome mRNA technology mrna vaccines Multiple Sclerosis Schizophrenia osteoporosis detection Parkinson's PDUFA pediatric health phage therapy pulmonary care surgical tech SurVaxM T1D ThyroidCancer VSee

Archives

Archives

1
2

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Obesity Review 2025: The Rise of Oralization, the Muscle Question, and a New Era of Access Pressure
Lucid Diligence Brief: Truemed $34m Series A to scale payment integration platform
Lucid Diligence Brief: Jacobio and AstraZeneca pan-KRAS asset deal
Oncology 2025 Review: Curative-Intent Expansion, ADC Acceleration, and the Operationalization of Immunotherapy
Lucid Diligence Brief: BioMarin to acquire Amicus Therapeutics for $4.8B

TAGS

ADC therapy Allurion Angelman Syndrome antimicrobiotics pipeline ASGCT 2025 asthma treatment CAR T Therapy CBD research CGM Chemical Pollution co-pilot Colorectal Cancer Columvi contraceptives DASH Diet Digital Inhaler dostarlimab exoskeleton Galderma GeoVax Glymphatic System HCPs HIV Research immunooncology India Pharma insulin access ISC 2025 Longevity industry mCRC Medical Breakthroughs microbiome mRNA technology mrna vaccines Multiple Sclerosis Schizophrenia osteoporosis detection Parkinson's PDUFA pediatric health phage therapy pulmonary care surgical tech SurVaxM T1D ThyroidCancer VSee

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
BioPharma and Tech News
LucidSearch
QuickAnswers

© 2025 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy